CompletedNot Applicable

BLAZE-Limiting Approach in NMOSD

China9 participantsStarted 2023-10-01

Plain-language summary

This is an observational cohort study based on data from the hospital-based NMOSD registry (Chinese Medical Research Registration Number MR-31-22-008563; ChiCTR2000030651). Between October 2023 (when eculizumab was approved for NMOSD in China) and February 2025, 26 consecutive patients with AQP4-IgG-positive NMOSD received eculizumab, and 9 of them were included in this study.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕. Patients with unresolved Neisseria meningitidis infection or severe infections that preclude the use of immunotherapy;
✕. Patients with severe comorbidities (such as heart failure, respiratory failure, severe hepatic or renal dysfunction, etc.);
✕. Patients with incomplete records of clinical symptoms and signs, as well as insufficient data on serum marker tests in their medical records.

What they're measuring

The change in disability status measured by the MRC scale score

Timeframe: 0, 1, 2, 3, 4, 8 weeks

The change in disability status

Timeframe: 0, 1, 2, 3, 4, 8 weeks

Trial details

NCT IDNCT06888622

SponsorHuashan Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-03-01

View on ClinicalTrials.gov More Neuromyelitis Optica Spectrum Disorders (NMOSD) trials